Albumin	B:C0001924
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
:	O
A	O
Novel	O
Prognostic	O
Index	O
of	O
Overall	O
Survival	O
in	O
Cisplatin	O
-	O
based	O
Chemotherapy	O
-	O
treated	O
Patients	O
with	O
Metastatic	O
Nasopharyngeal	I:C1377919
Carcinoma	I:C1377919
.	O

Albumin	O
-	O
to-	O
Alkaline	B:C0002059
Phosphatase	I:C0002059
Ratio	O
:	O
A	O
Novel	O
Prognostic	O
Index	O
of	O
Overall	O
Survival	O
in	O
Cisplatin	O
-	O
based	O
Chemotherapy	O
-	O
treated	O
Patients	O
with	O
Metastatic	O
Nasopharyngeal	I:C1377919
Carcinoma	I:C1377919
.	O

Albumin	O
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
:	O
A	O
Novel	O
Prognostic	B:C0220901
Index	O
of	O
Overall	O
Survival	O
in	O
Cisplatin	O
-	O
based	O
Chemotherapy	O
-	O
treated	O
Patients	O
with	O
Metastatic	O
Nasopharyngeal	I:C1377919
Carcinoma	I:C1377919
.	O

Albumin	O
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
:	O
A	O
Novel	O
Prognostic	O
Index	B:C0918012
of	O
Overall	O
Survival	O
in	O
Cisplatin	O
-	O
based	O
Chemotherapy	O
-	O
treated	O
Patients	O
with	O
Metastatic	O
Nasopharyngeal	I:C1377919
Carcinoma	I:C1377919
.	O

Albumin	O
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
:	O
A	O
Novel	O
Prognostic	O
Index	O
of	O
Overall	O
Survival	O
in	O
Cisplatin	B:C0008838
-	O
based	O
Chemotherapy	O
-	O
treated	O
Patients	O
with	O
Metastatic	O
Nasopharyngeal	I:C1377919
Carcinoma	I:C1377919
.	O

Albumin	O
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
:	O
A	O
Novel	O
Prognostic	O
Index	O
of	O
Overall	O
Survival	O
in	O
Cisplatin	O
-	O
based	O
Chemotherapy	B:C3665472
-	O
treated	O
Patients	O
with	O
Metastatic	O
Nasopharyngeal	I:C1377919
Carcinoma	I:C1377919
.	O

Albumin	O
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
:	O
A	O
Novel	O
Prognostic	O
Index	O
of	O
Overall	O
Survival	O
in	O
Cisplatin	O
-	O
based	O
Chemotherapy	O
-	O
treated	O
Patients	O
with	O
Metastatic	B:C1377919
Nasopharyngeal	I:C1377919
Carcinoma	I:C1377919
.	O

The	O
Albumin	B:C0001924
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
(	O
AAPR	O
)	O
has	O
been	O
recently	O
revealed	O
as	O
a	O
prognostic	O
index	O
for	O
hepatocellular	O
carcinoma	I:C2239176
,	O
whereas	O
its	O
role	O
in	O
metastatic	O
nasopharyngeal	I:C1377919
cancer	I:C1377919
(	O
nasopharyngeal	O
cancer	I:C1377919
)	O
remains	O
unclear	O
.	O

The	O
Albumin	O
-	O
to-	O
Alkaline	B:C0002059
Phosphatase	I:C0002059
Ratio	O
(	O
AAPR	O
)	O
has	O
been	O
recently	O
revealed	O
as	O
a	O
prognostic	O
index	O
for	O
hepatocellular	O
carcinoma	I:C2239176
,	O
whereas	O
its	O
role	O
in	O
metastatic	O
nasopharyngeal	I:C1377919
cancer	I:C1377919
(	O
nasopharyngeal	O
cancer	I:C1377919
)	O
remains	O
unclear	O
.	O

The	O
Albumin	O
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
(	O
AAPR	O
)	O
has	O
been	O
recently	O
revealed	O
as	O
a	O
prognostic	B:C0220901
index	O
for	O
hepatocellular	O
carcinoma	I:C2239176
,	O
whereas	O
its	O
role	O
in	O
metastatic	O
nasopharyngeal	I:C1377919
cancer	I:C1377919
(	O
nasopharyngeal	O
cancer	I:C1377919
)	O
remains	O
unclear	O
.	O

The	O
Albumin	O
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
(	O
AAPR	O
)	O
has	O
been	O
recently	O
revealed	O
as	O
a	O
prognostic	O
index	B:C0918012
for	O
hepatocellular	O
carcinoma	I:C2239176
,	O
whereas	O
its	O
role	O
in	O
metastatic	O
nasopharyngeal	I:C1377919
cancer	I:C1377919
(	O
nasopharyngeal	O
cancer	I:C1377919
)	O
remains	O
unclear	O
.	O

The	O
Albumin	O
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
(	O
AAPR	O
)	O
has	O
been	O
recently	O
revealed	O
as	O
a	O
prognostic	O
index	O
for	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
,	O
whereas	O
its	O
role	O
in	O
metastatic	O
nasopharyngeal	I:C1377919
cancer	I:C1377919
(	O
nasopharyngeal	O
cancer	I:C1377919
)	O
remains	O
unclear	O
.	O

The	O
Albumin	O
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
(	O
AAPR	O
)	O
has	O
been	O
recently	O
revealed	O
as	O
a	O
prognostic	O
index	O
for	O
hepatocellular	O
carcinoma	I:C2239176
,	O
whereas	O
its	O
role	O
in	O
metastatic	B:C1377919
nasopharyngeal	I:C1377919
cancer	I:C1377919
(	O
nasopharyngeal	O
cancer	I:C1377919
)	O
remains	O
unclear	O
.	O

The	O
Albumin	O
-	O
to-	O
Alkaline	O
Phosphatase	I:C0002059
Ratio	O
(	O
AAPR	O
)	O
has	O
been	O
recently	O
revealed	O
as	O
a	O
prognostic	O
index	O
for	O
hepatocellular	O
carcinoma	I:C2239176
,	O
whereas	O
its	O
role	O
in	O
metastatic	O
nasopharyngeal	I:C1377919
cancer	I:C1377919
(	O
nasopharyngeal	B:C1377919
cancer	I:C1377919
)	O
remains	O
unclear	O
.	O

The	O
aim	O
of	O
this	O
study	B:C2603343
was	O
to	O
evaluate	O
the	O
clinical	O
value	O
of	O
AAPR	O
in	O
patients	O
with	O
metastatic	O
NPC	I:C1377919
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	B:C0220825
the	O
clinical	O
value	O
of	O
AAPR	O
in	O
patients	O
with	O
metastatic	O
NPC	I:C1377919
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
clinical	O
value	O
of	O
AAPR	O
in	O
patients	O
with	O
metastatic	B:C1377919
NPC	I:C1377919
.	O

We	O
retrospectively	O
reviewed	O
209	O
metastatic	B:C1377919
NPC	I:C1377919
patients	O
treated	O
with	I:C0332293
cisplatin	O
-	O
based	O
regimens	O
.	O

We	O
retrospectively	O
reviewed	O
209	O
metastatic	O
NPC	I:C1377919
patients	O
treated	B:C0332293
with	I:C0332293
cisplatin	O
-	O
based	O
regimens	O
.	O

We	O
retrospectively	O
reviewed	O
209	O
metastatic	O
NPC	I:C1377919
patients	O
treated	O
with	I:C0332293
cisplatin	B:C0008838
-	O
based	O
regimens	O
.	O

We	O
retrospectively	O
reviewed	O
209	O
metastatic	O
NPC	I:C1377919
patients	O
treated	O
with	I:C0332293
cisplatin	O
-	O
based	O
regimens	B:C0040808
.	O

Univariate	O
and	O
multivariate	B:C0038953
survival	I:C0038953
analyses	I:C0038953
were	O
conducted	O
using	O
the	O
Cox	O
proportional	I:C0010235
hazards	I:C0010235
regression	I:C0010235
methodology	I:C0010235
.	O

Univariate	O
and	O
multivariate	O
survival	I:C0038953
analyses	I:C0038953
were	O
conducted	O
using	O
the	O
Cox	B:C0010235
proportional	I:C0010235
hazards	I:C0010235
regression	I:C0010235
methodology	I:C0010235
.	O

The	O
optimal	O
cutoff	O
level	O
of	O
AAPR	O
for	O
assessing	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
0.447	O
,	O
which	O
was	O
determined	O
by	O
R	B:C0037589
software	I:C0037589
.	O

An	O
AAPR	O
less	O
than	O
0.447	O
was	O
significantly	O
associated	O
with	O
a	O
higher	O
lactate	B:C1318159
dehydrogenase	I:C1318159
(	I:C1318159
LDH	I:C1318159
)	I:C1318159
level	I:C1318159
(	O
273	O
vs.	O
185	O
U/L	O
,	O
P	O
=	O
0.004	O
)	O
,	O
a	O
higher	O
EBV	I:C3808257
DNA	I:C3808257
viral	I:C3808257
load	I:C3808257
(	O
5.59	O
×10	O
(	O
5	O
)	O
vs.	O
3.49	O
×10	O
(	O
4	O
)	O
copies	O
/	O
ml	O
,	O
P	O
=	O
0.001	O
)	O
,	O
and	O
more	O
liver	O
and	O
bone	O
metastases	I:C0153690
(	O
P	O
=	O
0.005	O
and	O
P	O
=	O
0.001	O
,	O
respectively	O
)	O
.	O

An	O
AAPR	O
less	O
than	O
0.447	O
was	O
significantly	O
associated	O
with	O
a	O
higher	O
lactate	O
dehydrogenase	I:C1318159
(	I:C1318159
LDH	I:C1318159
)	I:C1318159
level	I:C1318159
(	O
273	O
vs.	O
185	O
U/L	O
,	O
P	O
=	O
0.004	O
)	O
,	O
a	O
higher	B:C3808257
EBV	I:C3808257
DNA	I:C3808257
viral	I:C3808257
load	I:C3808257
(	O
5.59	O
×10	O
(	O
5	O
)	O
vs.	O
3.49	O
×10	O
(	O
4	O
)	O
copies	O
/	O
ml	O
,	O
P	O
=	O
0.001	O
)	O
,	O
and	O
more	O
liver	O
and	O
bone	O
metastases	I:C0153690
(	O
P	O
=	O
0.005	O
and	O
P	O
=	O
0.001	O
,	O
respectively	O
)	O
.	O

An	O
AAPR	O
less	O
than	O
0.447	O
was	O
significantly	O
associated	O
with	O
a	O
higher	O
lactate	O
dehydrogenase	I:C1318159
(	I:C1318159
LDH	I:C1318159
)	I:C1318159
level	I:C1318159
(	O
273	O
vs.	O
185	O
U/L	O
,	O
P	O
=	O
0.004	O
)	O
,	O
a	O
higher	O
EBV	I:C3808257
DNA	I:C3808257
viral	I:C3808257
load	I:C3808257
(	O
5.59	O
×10	O
(	O
5	O
)	O
vs.	O
3.49	O
×10	O
(	O
4	O
)	O
copies	O
/	O
ml	O
,	O
P	O
=	O
0.001	O
)	O
,	O
and	O
more	O
liver	B:C0494165
and	O
bone	O
metastases	I:C0153690
(	O
P	O
=	O
0.005	O
and	O
P	O
=	O
0.001	O
,	O
respectively	O
)	O
.	O

An	O
AAPR	O
less	O
than	O
0.447	O
was	O
significantly	O
associated	O
with	O
a	O
higher	O
lactate	O
dehydrogenase	I:C1318159
(	I:C1318159
LDH	I:C1318159
)	I:C1318159
level	I:C1318159
(	O
273	O
vs.	O
185	O
U/L	O
,	O
P	O
=	O
0.004	O
)	O
,	O
a	O
higher	O
EBV	I:C3808257
DNA	I:C3808257
viral	I:C3808257
load	I:C3808257
(	O
5.59	O
×10	O
(	O
5	O
)	O
vs.	O
3.49	O
×10	O
(	O
4	O
)	O
copies	O
/	O
ml	O
,	O
P	O
=	O
0.001	O
)	O
,	O
and	O
more	O
liver	O
and	O
bone	B:C0153690
metastases	I:C0153690
(	O
P	O
=	O
0.005	O
and	O
P	O
=	O
0.001	O
,	O
respectively	O
)	O
.	O

Our	O
study	B:C2603343
suggested	O
that	O
the	O
AAPR	O
might	O
be	O
a	O
novel	O
prognostic	O
factor	O
in	O
metastatic	O
NPC	I:C1377919
patients	O
treated	O
with	I:C0332293
cisplatin	O
-	O
based	O
regimens	O
.	O

Our	O
study	O
suggested	O
that	O
the	O
AAPR	O
might	O
be	O
a	O
novel	O
prognostic	B:C0220901
factor	O
in	O
metastatic	O
NPC	I:C1377919
patients	O
treated	O
with	I:C0332293
cisplatin	O
-	O
based	O
regimens	O
.	O

Our	O
study	O
suggested	O
that	O
the	O
AAPR	O
might	O
be	O
a	O
novel	O
prognostic	O
factor	O
in	O
metastatic	B:C1377919
NPC	I:C1377919
patients	O
treated	O
with	I:C0332293
cisplatin	O
-	O
based	O
regimens	O
.	O

Our	O
study	O
suggested	O
that	O
the	O
AAPR	O
might	O
be	O
a	O
novel	O
prognostic	O
factor	O
in	O
metastatic	O
NPC	I:C1377919
patients	O
treated	B:C0332293
with	I:C0332293
cisplatin	O
-	O
based	O
regimens	O
.	O

Our	O
study	O
suggested	O
that	O
the	O
AAPR	O
might	O
be	O
a	O
novel	O
prognostic	O
factor	O
in	O
metastatic	O
NPC	I:C1377919
patients	O
treated	O
with	I:C0332293
cisplatin	B:C0008838
-	O
based	O
regimens	O
.	O

Our	O
study	O
suggested	O
that	O
the	O
AAPR	O
might	O
be	O
a	O
novel	O
prognostic	O
factor	O
in	O
metastatic	O
NPC	I:C1377919
patients	O
treated	O
with	I:C0332293
cisplatin	O
-	O
based	O
regimens	B:C0040808
.	O

However	O
,	O
a	O
prospective	B:C0033522
study	I:C0033522
to	O
validate	O
its	O
prognostic	O
value	O
is	O
needed	O
,	O
and	O
the	O
mechanisms	O
underlying	O
the	O
low	O
AAPR	O
and	O
poor	O
survival	O
in	O
metastatic	O
NPC	I:C1377919
need	O
to	O
be	O
further	O
investigated	O
.	O

However	O
,	O
a	O
prospective	O
study	I:C0033522
to	O
validate	O
its	O
prognostic	B:C0220901
value	O
is	O
needed	O
,	O
and	O
the	O
mechanisms	O
underlying	O
the	O
low	O
AAPR	O
and	O
poor	O
survival	O
in	O
metastatic	O
NPC	I:C1377919
need	O
to	O
be	O
further	O
investigated	O
.	O

However	O
,	O
a	O
prospective	O
study	I:C0033522
to	O
validate	O
its	O
prognostic	O
value	O
is	O
needed	O
,	O
and	O
the	O
mechanisms	O
underlying	O
the	O
low	O
AAPR	O
and	O
poor	O
survival	O
in	O
metastatic	B:C1377919
NPC	I:C1377919
need	O
to	O
be	O
further	O
investigated	O
.	O

